-
JXY Reprograms Macrophages in Colitis-Associated CRC
2026-09-12
The reference study shows that Jiedu Xiaozheng Yin limits colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like state through TLR4-associated signaling. Its combination of tumor phenotyping, macrophage functional assays, transcriptional readouts, and pathway antagonism provides a useful framework for studying inflammation-driven tumor progression.
-
Stat3 in Fyn-Driven Dopaminergic Neurodegeneration
2026-09-11
This zebrafish study identifies Stat3 as a downstream effector linking constitutively active Fyn kinase to dopaminergic neuron loss, mitochondrial abnormalities, and microglia-associated inflammation. Its combination of cell-type-specific genetics, live imaging, transcriptomics, and pathway inhibition provides a mechanistic framework for studying neurodegeneration and designing future functional gene studies.
-
TUNEL Signals in the Pyroptosis Era
2026-09-11
A translational guide to interpreting TUNEL signals alongside pyroptosis biology, with practical strategies for tissue, cell-based, and combination-therapy studies.
-
Epinephrine Bitartrate: Research Workflow Guide
2026-09-10
Build reproducible α- and β-adrenergic experiments with a practical workflow for dose selection, route comparison, pharmacokinetic sampling, and functional readouts. The guide translates canine intranasal findings into assay choices while preserving the limitations of a non-selective agonist.
-
X-Gal Workflows for Cloning and β-Galactosidase Assays
2026-09-10
Use X-Gal to turn lacZα-based clone selection into a rapid visual decision, then extend the same logic to reporter validation and β-galactosidase activity assay workflows. This guide combines practical plating parameters, failure analysis, and a careful connection to activity-dependent receptor biology.
-
Dimethoxy-Tolazoline Derivatives at α-Adrenoceptors
2026-09-09
This 1985 study showed that the position of two methoxy groups on the tolazoline aromatic ring strongly determines α1- and α2-adrenoreceptor efficacy, selectivity, and antagonist activity. By combining isolated-organ pharmacology with radioligand binding, the authors identified distinct derivative profiles that remain useful for interpreting structure–activity relationships and selecting receptor probes.
-
SB203580 Beyond Inhibition: Translational Strategy
2026-09-09
A mechanistic and translational framework for using SB203580 to interrogate p38 signaling, distinguish pathway effects from adaptive resistance, and design more decision-ready experiments.
-
Magnetic Stimulation Targets GABRE in Schizophrenia
2026-09-08
A Molecular Psychiatry study identifies the GABAA receptor ε subunit, encoded by Gabre, as a region-specific mediator of schizophrenia-like behaviors in mice. By combining targeted magnetic stimulation with genetic loss- and gain-of-function models, the researchers connect left prelimbic-cortex GABRE regulation to synaptic abnormalities and implicate p62/SQSTM1–GABARAP signaling in the response.
-
v-Agatoxin-IVA and Neuronal Ca Channel Diversity
2026-09-08
Sidach and Mintz showed that v-Agatoxin-IVA remains a high-affinity P-type calcium-channel blocker but also produces low-affinity inhibition of N-type and related high-threshold currents at micromolar exposure. The study demonstrates why toxin concentration, membrane voltage, cell type, and orthogonal current controls must be considered before assigning native neuronal calcium-channel identity.
-
From EGFP Signal to Translational Evidence
2026-09-07
A strategic guide to using modified, capped EGFP mRNA as a mechanistic reporter for delivery, translation, innate immune response, and translational decision-making, informed by recent CRISPR-LNP research in choroidal neovascularization.
-
Coelenterazine Workflows for ROS Reporter Assays
2026-09-05
Coelenterazine links luciferase reporter output with chemiluminescent detection of superoxide anion and peroxynitrite. This practical guide shows how to build controlled reporter, BRET, oxidative stress, HTS, and cancer-imaging workflows while separating biological signal from substrate and solvent effects.
-
DON Liver Injury: Mitophagy and Nrf2 Disruption
2026-09-05
The reference study proposes that deoxynivalenol-induced hepatotoxicity arises from two converging processes: excessive PINK1/Parkin-mediated mitophagy and suppression of the p62-Keap1-Nrf2 antioxidant defense pathway. Its inhibitor, siRNA, and p62-rescue experiments move the interpretation beyond association and provide a mechanistic framework for studying toxin-related mitochondrial injury.
-
YAP–TEAD Control of Surface Ectoderm Super-Enhancers
2026-09-04
Wang et al. identify a super-enhancer regulatory landscape that coordinates early surface ectoderm commitment from pluripotent stem cells and position YAP–TEAD as an upstream activator of this process. By combining 3D genomic profiling with CRISPR-dCas9 perturbation and transcription-factor analysis, the study connects enhancer architecture to lineage progression and provides a framework for evaluating epithelial differentiation systems.
-
Prochlorperazine Trial Design for Acute Mountain Sickness
2026-09-04
This 2024 randomized controlled trial protocol proposes prochlorperazine maleate as a novel preventive treatment for acute mountain sickness (AMS), based on shared clinical features with migraine and possible respiratory stimulation. Its controlled rapid-ascent design, placebo comparison, and repeated Lake Louise Questionnaire assessments provide a practical framework for testing efficacy, although the protocol does not yet provide clinical outcome data.
-
NS7a, Apoptosis, and SADS-CoV Immune Evasion
2026-09-03
The reference study identifies an AIFM1–caspase-6–caspase-3–IRF3 axis through which SADS-CoV NS7a promotes apoptosis, suppresses type III interferon, and enhances viral replication. Its cell and piglet experiments support apoptosis inhibition as a mechanistic antiviral strategy, while also showing why pathway-selective validation remains important.